Alivus Life Sciences Ltd (ALIVUS) is currently trading at 1,355.15 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Alivus Life Sciences Limited, formerly Glenmark Life Sciences, specializes in developing, manufacturing, and marketing Active Pharmaceutical Ingredients (APIs) across various therapeutic segments. The company's Q3 FY26 revenue saw substantial growth of 14.4% QoQ, driven by recovery in the CDMO segment and robust demand in regulated markets such as Europe and Japan. Alivus has successfully expanded its capacity, notably in Dahej and Ankleshwar, aligning with its strategy of supporting sustained growth in its CDMO and API businesses. The company reported its highest ever EBITDA margin of 36.4% in Q3 FY26, supported by new product launches and favorable product mixes. Alivus is strategically focused on expanding its CDMO business, aiming for new project wins and leveraging operational efficiencies to sustain margin expansion.

Over the past 52 weeks, Alivus Life Sciences Ltd has traded between a low of ₹830.00 and a high of ₹1,495.30. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Alivus Life Sciences Ltd has a market capitalization of approximately 17,005.69. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Alivus Life Sciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 28.20 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 17,005.69 Cr, Alivus Life Sciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Alivus Life Sciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Alivus Life Sciences Ltd is 28.20. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Revenue from operations rose 6.4% YoY to ₹640.41 crore and standalone PAT rose 31.8% YoY to ₹160.08 crore.

Standalone revenue from operations was ₹640.41 crore and PAT was ₹160.08 crore in Q1 FY27.

Revenue from operations was ₹5,879.80 million and net profit (PAT) was ₹1,300.26 million in Q2FY26.

The 10,000 crore Biopharma Shakti scheme supports the domestic production of biologics and biosimilars, providing a strategic framework for Alivus to expand its advanced API and biopharma manufacturing capabilities.